Mr. Joshua Bartch reports
MYDECINE INNOVATIONS GROUP, INC. ANNOUNCES GRANT OF STOCK OPTIONS
Mydecine Innovations Group Inc. has granted stock options to purchase up to one million common shares of the company to Michael A. Connolly, chief compliance officer and a director of the company, pursuant to its stock option plan. Each option is exercisable for a period of five years at an exercise price of 26 cents per common share, subject to regulatory regulations.
About Mydecine Innovations Group Inc.
Mydecine Innovations is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine's experienced cross-functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions and fungtional mushroom vitality products. Its portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health and NeuroPharm, focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.